Dr Stacey Rudd
Postdoctoral Fellow – Inorganic Chemistry
School of Chemistry
38 Scholarly works
5 Projects
HIGHLIGHTS
2026
Journal article
An Evaluation of Cage Amine Sarcophagine Ligands for the Synthesis of Cobalt Radiopharmaceuticals
DOI: 10.1021/acs.inorgchem.6c014822026
Journal article
Toward photodynamic detection and photodynamic therapy of tumours over-expressing carbonic anhydrase IX with a phosphorescent organometallic iridium(iii) antibody conjugate
DOI: 10.1039/d5sc07715j2026
Journal article
Looking backward to move forward: a chemist’s perspective on the future of radiopharmaceuticals
DOI: 10.1007/s00775-025-02130-z2026
Journal article
Abstract PS4-04-08: Radioimmunotherapy using 64/67Copper labelled trastuzumab in mice bearing HER2-positve xenografts as a model for breast cancer therapy
DOI: 10.1158/1557-3265.sabcs25-ps4-04-082023
Research grants (other domestic)
Agilent 6545XT AdvanceBio LC/Q-TOF
2023
Research contracts (non-grants)
Development of Novel Theranostics Heterobivalent Sarcophagine Derivatives
2022
Research grants (ARC, NHMRC, MRFF)
Illumination of Immune Checkpoint Therapy of Cancer: Molecular Imaging of Immunity With Copper Radiopharmaceuticals
RECENT SCHOLARLY WORKS
2026
Journal article
Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer
DOI: 10.1002/chem.710112025
Journal article
Abstract 573: Radioimmunotherapy using 64/67copper labelled trastuzumab in mice bearing HER2-positve xenografts as a model for breast cancer therapy
DOI: 10.1158/1538-7445.am2025-5732025
Journal article
Abstract 2149: Copper-67 based targeted radioligand therapy to the somatostatin receptor 2 (SSTR2) provides added efficacy and may prime small cell lung cancer for immunotherapy
DOI: 10.1158/1538-7445.am2025-21492025
Journal article
Abstract 572: Development of a targeted copper theranostic to fibroblast activation protein (FAP) which shows high uptake and long-term retention at the tumor site
DOI: 10.1158/1538-7445.am2025-5722025
Journal article
Abstract B005: Copper-67 based targeted radioligand therapy to the somatostatin receptor 2 (SSTR2) provides added efficacy and may prime small cell lung cancer for immunotherapy
DOI: 10.1158/1557-3265.targetedtherap-b0052025
Journal article
Potential theranostics of breast cancer with copper-64/67 sarcophagine-trastuzumab
DOI: 10.1039/d4sc06969b
RECENT PROJECTS
2023
Research contracts (non-grants)
Development of a Sarcophagine Platform for Modulating Biodistribution of Biomolecules and Development of Novel Theranostics Heterobivalent Sarcophagine Derivatives
2023
Research Grant
Imaging Trastuzumab Deruxtecan: Defining the Relationship Between PET Uptake and Response